P356: SUBGROUP ANALYSES OF KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL) IN ZUMA-3
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000844312.20412.89 |
| _version_ | 1827335137226915840 |
|---|---|
| author | B. D. Shah R. D. Cassaday J. H. Park R. Houot O. O. Oluwole A. C. Logan N. Boissel T. Leguay M. R. Bishop M. S. Topp D. Tzachanis K. M. O’Dwyer M. L. Arellano Y. Lin M. R. Baer G. J. Schiller M. Subklewe M. Abedi M. C. Minnema W. G. Wierda D. J. DeAngelo P. Stiff D. Jeyakumar J. Dong S. Adhikary L. Zhou P. C. Schuberth B. Kharabi Masouleh A. Ghobadi |
| author_facet | B. D. Shah R. D. Cassaday J. H. Park R. Houot O. O. Oluwole A. C. Logan N. Boissel T. Leguay M. R. Bishop M. S. Topp D. Tzachanis K. M. O’Dwyer M. L. Arellano Y. Lin M. R. Baer G. J. Schiller M. Subklewe M. Abedi M. C. Minnema W. G. Wierda D. J. DeAngelo P. Stiff D. Jeyakumar J. Dong S. Adhikary L. Zhou P. C. Schuberth B. Kharabi Masouleh A. Ghobadi |
| author_sort | B. D. Shah |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:10:51Z |
| format | Article |
| id | doaj.art-1f7bc2c1e7834a639f9bc217116e1ede |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:10:51Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-1f7bc2c1e7834a639f9bc217116e1ede2024-03-02T07:47:15ZengWileyHemaSphere2572-92412022-06-01625625710.1097/01.HS9.0000844312.20412.89202206003-00256P356: SUBGROUP ANALYSES OF KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL) IN ZUMA-3B. D. Shah0R. D. Cassaday1J. H. Park2R. Houot3O. O. Oluwole4A. C. Logan5N. Boissel6T. Leguay7M. R. Bishop8M. S. Topp9D. Tzachanis10K. M. O’Dwyer11M. L. Arellano12Y. Lin13M. R. Baer14G. J. Schiller15M. Subklewe16M. Abedi17M. C. Minnema18W. G. Wierda19D. J. DeAngelo20P. Stiff21D. Jeyakumar22J. Dong23S. Adhikary24L. Zhou25P. C. Schuberth26B. Kharabi Masouleh27A. Ghobadi281 Moffitt Cancer Center, Tampa, FL2 University of Washington, Fred Hutchinson, Seattle Cancer Care Alliance, Seattle WA3 Memorial Sloan Kettering Cancer Center, New York, NY, United States of America4 CHU Rennes, University Hospital Rennes, Inserm & EFS, Rennes, France5 Vanderbilt University Cancer Center, Nashville, TN6 UCSF Medical Center, San Francisco, CA, United States of America7 Hôpital Saint-Louis, Paris8 Service d’hématologie clinique et thérapie cellulaire Hôpital du Haut-Leveque CHU de Bordeaux, Bordeaux, France9 The University of Chicago Medicine, Chicago, IL, United States of America10 Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany11 University of California San Diego, San Deigo, CA12 Wilmot Cancer Institute of University of Rochester, Rochester, NY13 Winship Cancer Institute of Emory University, Atlanta, GA14 Mayo Clinic, Rochester, MN15 University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD16 David Geffen School of Medicine at UCLA, Los Angeles, CA, United States of America17 Ludwig-Maximilians-Universität München, Munich, Germany18 University of California Davis Comprehensive Cancer Center, Sacramento, CA, United States of America19 University Medical Center Utrecht, on behalf of HOVON/LLPC, Utrecht, Netherlands20 The University of Texas MD Anderson Cancer Center, Houston, TX21 Dana-Farber Cancer Institute, Boston, MA22 Loyola University Chicago Stritch School of Medicine, Maywood, IL23 University of California Irvine Medical Center, Irvine, CA24 Kite, a Gilead Company, Santa Monica, CA24 Kite, a Gilead Company, Santa Monica, CA24 Kite, a Gilead Company, Santa Monica, CA24 Kite, a Gilead Company, Santa Monica, CA24 Kite, a Gilead Company, Santa Monica, CA25 Washington University School of Medicine, St Louis, MO, United States of Americahttp://journals.lww.com/10.1097/01.HS9.0000844312.20412.89 |
| spellingShingle | B. D. Shah R. D. Cassaday J. H. Park R. Houot O. O. Oluwole A. C. Logan N. Boissel T. Leguay M. R. Bishop M. S. Topp D. Tzachanis K. M. O’Dwyer M. L. Arellano Y. Lin M. R. Baer G. J. Schiller M. Subklewe M. Abedi M. C. Minnema W. G. Wierda D. J. DeAngelo P. Stiff D. Jeyakumar J. Dong S. Adhikary L. Zhou P. C. Schuberth B. Kharabi Masouleh A. Ghobadi P356: SUBGROUP ANALYSES OF KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL) IN ZUMA-3 HemaSphere |
| title | P356: SUBGROUP ANALYSES OF KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL) IN ZUMA-3 |
| title_full | P356: SUBGROUP ANALYSES OF KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL) IN ZUMA-3 |
| title_fullStr | P356: SUBGROUP ANALYSES OF KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL) IN ZUMA-3 |
| title_full_unstemmed | P356: SUBGROUP ANALYSES OF KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL) IN ZUMA-3 |
| title_short | P356: SUBGROUP ANALYSES OF KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL) IN ZUMA-3 |
| title_sort | p356 subgroup analyses of kte x19 an anti cd19 chimeric antigen receptor car t cell therapy in adult patients with relapsed or refractory b cell acute lymphoblastic leukemia r r b all in zuma 3 |
| url | http://journals.lww.com/10.1097/01.HS9.0000844312.20412.89 |
| work_keys_str_mv | AT bdshah p356subgroupanalysesofktex19ananticd19chimericantigenreceptorcartcelltherapyinadultpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemiarrballinzuma3 AT rdcassaday p356subgroupanalysesofktex19ananticd19chimericantigenreceptorcartcelltherapyinadultpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemiarrballinzuma3 AT jhpark p356subgroupanalysesofktex19ananticd19chimericantigenreceptorcartcelltherapyinadultpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemiarrballinzuma3 AT rhouot p356subgroupanalysesofktex19ananticd19chimericantigenreceptorcartcelltherapyinadultpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemiarrballinzuma3 AT oooluwole p356subgroupanalysesofktex19ananticd19chimericantigenreceptorcartcelltherapyinadultpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemiarrballinzuma3 AT aclogan p356subgroupanalysesofktex19ananticd19chimericantigenreceptorcartcelltherapyinadultpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemiarrballinzuma3 AT nboissel p356subgroupanalysesofktex19ananticd19chimericantigenreceptorcartcelltherapyinadultpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemiarrballinzuma3 AT tleguay p356subgroupanalysesofktex19ananticd19chimericantigenreceptorcartcelltherapyinadultpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemiarrballinzuma3 AT mrbishop p356subgroupanalysesofktex19ananticd19chimericantigenreceptorcartcelltherapyinadultpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemiarrballinzuma3 AT mstopp p356subgroupanalysesofktex19ananticd19chimericantigenreceptorcartcelltherapyinadultpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemiarrballinzuma3 AT dtzachanis p356subgroupanalysesofktex19ananticd19chimericantigenreceptorcartcelltherapyinadultpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemiarrballinzuma3 AT kmodwyer p356subgroupanalysesofktex19ananticd19chimericantigenreceptorcartcelltherapyinadultpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemiarrballinzuma3 AT mlarellano p356subgroupanalysesofktex19ananticd19chimericantigenreceptorcartcelltherapyinadultpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemiarrballinzuma3 AT ylin p356subgroupanalysesofktex19ananticd19chimericantigenreceptorcartcelltherapyinadultpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemiarrballinzuma3 AT mrbaer p356subgroupanalysesofktex19ananticd19chimericantigenreceptorcartcelltherapyinadultpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemiarrballinzuma3 AT gjschiller p356subgroupanalysesofktex19ananticd19chimericantigenreceptorcartcelltherapyinadultpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemiarrballinzuma3 AT msubklewe p356subgroupanalysesofktex19ananticd19chimericantigenreceptorcartcelltherapyinadultpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemiarrballinzuma3 AT mabedi p356subgroupanalysesofktex19ananticd19chimericantigenreceptorcartcelltherapyinadultpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemiarrballinzuma3 AT mcminnema p356subgroupanalysesofktex19ananticd19chimericantigenreceptorcartcelltherapyinadultpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemiarrballinzuma3 AT wgwierda p356subgroupanalysesofktex19ananticd19chimericantigenreceptorcartcelltherapyinadultpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemiarrballinzuma3 AT djdeangelo p356subgroupanalysesofktex19ananticd19chimericantigenreceptorcartcelltherapyinadultpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemiarrballinzuma3 AT pstiff p356subgroupanalysesofktex19ananticd19chimericantigenreceptorcartcelltherapyinadultpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemiarrballinzuma3 AT djeyakumar p356subgroupanalysesofktex19ananticd19chimericantigenreceptorcartcelltherapyinadultpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemiarrballinzuma3 AT jdong p356subgroupanalysesofktex19ananticd19chimericantigenreceptorcartcelltherapyinadultpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemiarrballinzuma3 AT sadhikary p356subgroupanalysesofktex19ananticd19chimericantigenreceptorcartcelltherapyinadultpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemiarrballinzuma3 AT lzhou p356subgroupanalysesofktex19ananticd19chimericantigenreceptorcartcelltherapyinadultpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemiarrballinzuma3 AT pcschuberth p356subgroupanalysesofktex19ananticd19chimericantigenreceptorcartcelltherapyinadultpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemiarrballinzuma3 AT bkharabimasouleh p356subgroupanalysesofktex19ananticd19chimericantigenreceptorcartcelltherapyinadultpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemiarrballinzuma3 AT aghobadi p356subgroupanalysesofktex19ananticd19chimericantigenreceptorcartcelltherapyinadultpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemiarrballinzuma3 |